339 related articles for article (PubMed ID: 21942841)
1. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor cytotoxic T lymphocytes targeting solid tumors: ready for clinical trials.
Rossig C
Cytotherapy; 2012 Jan; 14(1):4-6. PubMed ID: 22103944
[No Abstract] [Full Text] [Related]
3. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
[TBL] [Abstract][Full Text] [Related]
4. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells.
Kurokawa T; Oelke M; Mackensen A
Int J Cancer; 2001 Mar; 91(6):749-56. PubMed ID: 11275975
[TBL] [Abstract][Full Text] [Related]
5. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
6. Human accessory cells activate fresh, normal, tumor-distant T lymphocytes but not tumor-infiltrating T lymphocytes to lyse autologous tumor cells in a primary cytotoxic T lymphocyte assay in renal cell carcinoma.
Kramer G; Steiner GE; Paiha S; Handisurya A; Djavan B; Mallone R; Marberger M
Eur Urol; 2001 Oct; 40(4):427-33. PubMed ID: 11713398
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
8. Clinical course and immune response of a renal cell carcinoma patient to adoptive transfer of autologous cytotoxic T lymphocytes.
Kawai K; Saijo K; Oikawa T; Morishita Y; Noguchi M; Ohno T; Akaza H
Clin Exp Immunol; 2003 Nov; 134(2):264-9. PubMed ID: 14616786
[TBL] [Abstract][Full Text] [Related]
9. Case report: long-lasting response in a patient with metastatic renal cell cancer receiving antitumor cytotoxic T lymphocytes.
Secondino S; Turin I; Montini E; Porta C; Maccario R; Pedrazzoli P; Montagna D
Tumori; 2013; 99(6):282e-4e. PubMed ID: 24503804
[TBL] [Abstract][Full Text] [Related]
10. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer.
Santin AD; Bellone S; Palmieri M; Bossini B; Cane' S; Bignotti E; Roman JJ; Cannon MJ; Pecorelli S
Int J Gynecol Cancer; 2004; 14(1):64-75. PubMed ID: 14764031
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
12. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
13. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
[TBL] [Abstract][Full Text] [Related]
15. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
16. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.
Santin AD; Bellone S; Ravaggi A; Pecorelli S; Cannon MJ; Parham GP
Obstet Gynecol; 2000 Sep; 96(3):422-30. PubMed ID: 10960637
[TBL] [Abstract][Full Text] [Related]
17. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
Front Immunol; 2018; 9():14. PubMed ID: 29403496
[TBL] [Abstract][Full Text] [Related]
19. Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic T lymphocytes.
Soda H; Koda K; Yasutomi J; Oda K; Takiguchi N; Saito N; Nakajima N
J Surg Oncol; 1999 Dec; 72(4):211-7. PubMed ID: 10589036
[TBL] [Abstract][Full Text] [Related]
20. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
